Immuneering Corp (IMRX) stock
Close on Nov 13, 2026Market cap $240.27MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $240.27M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.42
- Dividend yield
- –
- Free cash flow yield
- -25.72%
Fundamentals
- Net income
- -$66.50M
- EPS, diluted
- -$1.03
- Free cash flow
- -$61.81M
- Book value per share
- $2.61
- Diluted shares
- 65M
Trading
- Next earnings
- Mar 5, 2027 (estimated, before the open)
- Previous close
- $3.67
- Open
- $3.71
- Day's range
- $3.54 – $3.75
- Volume
- 849,190
- Average volume (20 days)
- 749,297
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- 1.18
- 52-week range
- $3.35 – $8.48
- RSI (14 days)
- 47.4
- Volatility (1 year)
- 81.1%
- Relative volume
- 1.18×
- WACC
- 11.0%
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | IMRX | S&P 500 | Difference | IMRX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +4.2% | -3.0% | +7.3 pts | ||
| 3 months | -28.7% | -2.8% | −25.9 pts | ||
| Year to date | -43.6% | +11.5% | −55.1 pts | ||
| 1 year | -42.5% | +13.5% | −55.9 pts | ||
| 3 years | -23.3% | +77.7% | −101.0 pts | -8.5% | +21.1% |
| 5 years | -86.7% | +72.6% | −159.3 pts | -33.2% | +11.5% |
| 10 years | +37000.0% | +308.2% | +36691.8 pts | +80.7% | +15.1% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Immuneering filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- News
About Immuneering
Pharmaceutical Preparations
The company is a clinical-stage oncology biotechnology firm that develops small-molecule cancer therapeutics called Deep Cyclic Inhibitors. Its drug discovery and development platform combines high-throughput bioinformatics with proprietary three-dimensional humanized tumor growth assays to target core cellular signaling pathways, primarily the mitogen-activated protein kinase cascade. Its lead clinical candidate is atebimetinib, an oral MEK inhibitor under evaluation for solid tumors such as pancreatic and lung cancers. The development pipeline also includes envometinib, an allosteric MEK inhibitor, alongside early-stage discovery programs. The company previously provided computational services to pharmaceutical and biotechnology collaborators, but now focuses on developing treatments for cancer patients.
Company profile, executives and historyImmuneering stock: common questions
What is Immuneering's stock price?
IMRX closed at $3.71 on Nov 13, 2026, up 1.09% on the day. Over the past 52 weeks it traded between $3.35 and $8.48.
What is Immuneering's market cap?
Immuneering was worth $240.27M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is IMRX's P/E ratio?
Immuneering lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.03), so it has no meaningful P/E ratio.
Does Immuneering pay a dividend?
No. Immuneering has not paid a cash dividend over the last twelve months.
When does Immuneering report earnings next?
Immuneering is expected to report Q4 FY2026 results on Mar 5, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has IMRX stock performed over the past year?
Including dividends, IMRX returned -42.5% over the past year, against +13.5% for the S&P 500.
How many IMRX shares are sold short?
15M shares were sold short at the latest FINRA report, 25.49% of the float, or 19.2 days of average trading volume.
Who are Immuneering's competitors?
Companies most similar to Immuneering by business, industry and size include IMNM, CBIO, ELTX, SLS, APRE.
See a number that looks wrong?